secwatch / observer
8-K filed December 11, 2025, 6:59 PM ET ticker PHGE CIK 0001739174
other material confidence high sentiment negative materiality 0.85

BiomX subsidiary BiomX Ltd files for insolvency; Phase 2b study discontinued

BiomX Inc.

item 8.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001213900-25-120668
form_type
8-K
ticker
PHGE
cik
0001739174
company_name
BiomX Inc.
filed_at
2025-12-11T23:59:59+00:00
discovered_at
2026-05-14T18:02:40.288295+00:00
generated_at
2026-05-16T13:31:26.326238+00:00
sec_items
["8.01"]
event_type
other_material
sentiment
negative
materiality_score
0.85
calibrated_materiality_score
0.85
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001213900-25-120668
json_url
https://secwatch.observer/filing/0001213900-25-120668.json
markdown_url
https://secwatch.observer/filing/0001213900-25-120668.md
text_url
https://secwatch.observer/filing/0001213900-25-120668.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1739174/000121390025120668/0001213900-25-120668-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1739174/000121390025120668/ea0269336-8k_biomx.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Comparable filings

CWBHF

Charlotte's Web appoints BAT GC to board, closes debt conversion & US$10M investment

Charlotte's Web Holdings, Inc. June 1, 2026, 5:13 PM ET other_material Items 5.02, 5.07, 8.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

IMRX

Immuneering reports 17.3-month median OS in Phase 2a pancreatic trial of atebimetinib

Immuneering Corp June 1, 2026, 4:51 PM ET other_material Items 8.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

PRAX

Praxis Precision Medicines: Phase 2/3 vormatrigine study fails primary endpoint in focal seizures

Praxis Precision Medicines, Inc. June 1, 2026, 4:28 PM ET other_material Items 8.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

PLUR

Pluri gets EIB nod for loan talks; no enforcement until July 3 on €20M maturing today

Pluri Inc. June 1, 2026, 4:06 PM ET other_material Items 8.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

FULC

Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review

Fulcrum Therapeutics, Inc. June 1, 2026, 4:05 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR
accession 0001213900-25-120668
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.